Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29710134 | 0.92 | SLC6A2 (0.59) | OPRM1OPRD1OPRK1SLC6A2 | |
| SCHEMBL3817152 | 0.91 | OPRM1 (0.61) | OPRM1OPRD1OPRK1 | |
| SCHEMBL29702054 | 0.91 | OPRM1 (0.66) | OPRM1OPRD1OPRK1SLC6A2 | |
| SCHEMBL31412199 | 0.91 | OPRM1 (0.66) | OPRM1OPRD1OPRK1SLC6A2 | |
| SCHEMBL30833622 | 0.91 | OPRM1 (0.66) | OPRM1OPRD1OPRK1SLC6A2 | |
| SCHEMBL3812839 | 0.90 | OPRM1 (0.62) | OPRM1OPRD1OPRK1 | |
| SCHEMBL31553199 | 0.90 | SLC6A2 (0.60) | OPRM1OPRD1OPRK1SLC6A2 | |
| SCHEMBL30060726 | 0.90 | OPRM1 (0.69) | OPRM1OPRD1OPRK1SLC6A2 | |
| SCHEMBL30576724 | 0.89 | OPRM1 (0.62) | OPRM1OPRD1OPRK1 | |
| SCHEMBL10302843 | 0.88 | SLC6A2 (0.60) | OPRM1OPRD1OPRK1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| CN-113173970-B | Walnut meal anti-inflammatory peptide FPL and application thereof | 北京林业大学 | 2022-11-15 | — | — | CN | disclosed |
| CN-113173970-B | Walnut meal anti-inflammatory peptide FPL and application thereof | 北京林业大学 | 2022-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | OPRM1 804/4885OPRD1 402/4885OPRK1 2117/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | OPRM1 2130/4885OPRD1 2937/4885OPRK1 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.